d-Lenolate® 180ct — Full-Supply Olive Leaf Extract for Comprehensive Immune Support
d-Lenolate® 180 Capsules provides the complete, full-supply bottle of East Park Research's proprietary d-Lenolate olive leaf extract — delivering three months of daily immune support in one bottle.* This standardized oleuropein-rich extract provides sustained broad-spectrum antimicrobial, antioxidant, and cardiovascular support for individuals committed to olive leaf as a cornerstone of their natural health regimen.* The most economical size for regular users.*
Key Benefits
- 180-capsule supply — three months of daily maintenance or 6 weeks of therapeutic dosing
- d-Lenolate® proprietary process — maximum standardized oleuropein bioactivity*
- Broad-spectrum antimicrobial protection: viral, bacterial, fungal, and protozoal*
- Supports cardiovascular health through oleuropein's antioxidant and ACE-inhibiting properties*
- Best value size for long-term olive leaf users and chronic illness protocols
Who Is This For?
The 180-count d-Lenolate is ideal for individuals using olive leaf for long-term chronic infection management (Lyme, EBV, candida), daily immune maintenance, cardiovascular support, and anyone who's experienced the benefits of d-Lenolate and wants a sustained supply at the best value. Recommended by Michelle Tonkin ND for ongoing immune and infection protocols.
Frequently Asked Questions
Q: What is the daily maintenance dose vs. therapeutic dose?
A: Maintenance: 1–2 capsules daily. Therapeutic: 3–4 capsules 2–3 times daily. The 180-cap bottle supports 2–3 months at maintenance or 3–6 weeks at therapeutic doses.
Q: Is olive leaf safe for indefinite daily use?
A: Yes — olive leaf extract has an excellent long-term safety profile. It's a natural food-based compound (oleuropein is found in olive oil) with antioxidant effects that support ongoing health.
Q: Does d-Lenolate help with chronic fatigue?
A: Olive leaf's antiviral and antimicrobial properties make it particularly relevant for chronic fatigue associated with viral reactivation (EBV, CMV, HHV-6) — common underlying drivers of CFS/ME.*
